March 1992

Treatment of Systemic Sclerosis With Extracorporeal PhotochemotherapyResults of a Multicenter Trial

Author Affiliations

From the Departments of Dermatology (Drs Rook and Murphy) and Rheumatology (Dr Freundlich) and the General Clinical Research Center of the Hospital of the University of Pennsylvania, Philadelphia; Departments of Dermatology (Dr Jegasothy) and Rheumatology (Dr Steen), University of Pittsburgh (Pa) Medical Center; Department of Dermatology (Drs Perez, Heald, and Edelson) and the General Clinical Research Center of Yale University, New Haven, Conn; Departments of Rheumatology (Dr Barr) and Dermatology (Dr Massa), Loyola University, Maywood, Ill; Department of Rheumatology (Drs Jimenez and Varga) and the Blood Bank (Dr Ballas), Thomas Jefferson University Hospital, Philadelphia, Pa; Department of Dermatology, Ochsner Clinic, New Orleans, La (Drs Rietschel and Perniciaro); Department of Dermatology and the General Clinical Research Center, University of California at San Francisco (Dr Wintroub); and Department of Rheumatology (Drs Kahaleh and Istfan), Medical University of South Carolina, Charleston.

Arch Dermatol. 1992;128(3):337-346. doi:10.1001/archderm.1992.01680130051005

• Background and Design.—  In a pilot study of extracorporeal photochemotherapy, two patients with systemic sclerosis who received this therapy experienced significant clinical improvement. These results prompted the development of a multicenter trial to examine the benefit of extracorporeal photochemotherapy in the treatment of systemic sclerosis. Seventy-nine patients with systemic sclerosis of recent onset (mean symptom duration, 1.83 years) and progressive skin involvement during the preceding 6 months entered a randomized, parallel-group, single-blinded clinical trial comparing extracorporeal photochemotherapy treatments given on 2 consecutive days monthly with treatment with D-penicillamine at a maximum dose of 750 mg/d. Blinded clinical examiners evaluated skin severity score (thickness), percent surface area involvement, oral aperture, and hand closure. Serial skin biopsies and pulmonary function studies were also performed.

Results.—  Following 6 months of treatment, significant improvement in skin severity score occurred in 21 (68%) of 31 patients receiving photochemotherapy and in eight (32%) of 25 receiving D-penicillamine treatment, while significant worsening occurred in three (10%) of 31 receiving photochemotherapy and in eight (32%) of 25 receiving penicillamine treatment, thus indicating a significantly higher response rate for individuals who received photochemotherapy (P.02). At both the 6- and 10-month evaluation points, the mean skin severity score, mean percent skin involvement, and mean oral aperture measurements were significantly improved from baseline among those who received photochemotherapy. Mean right and left hand closure measurements had also improved significantly by 10 months of therapy. By comparison, among the patients treated with D-penicillamine, none of the parameters of cutaneous disease had improved significantly after 6 months of therapy, although for those individuals in whom treatment was continued, the mean skin severity score and mean percent skin involvement had improved by 10 months. Skin biopsy studies revealed a correlation between clinical improvement and decreased thickness of the dermal layer. Adverse effects of extracorporeal photochemotherapy were minimal and did not require discontinuation of treatment in any of the patients receiving this therapy; six patients permanently discontinued the use of D-pencillamine treatment due to adverse effects.

Conclusions.—  For patients with systemic sclerosis of recent onset, extracorporeal photochemotherapy is a well-tolerated treatment that may partially reverse the process that results in cutaneous sclerosis.(Arch Dermatol. 1992;128:337-346)